Long-term outcomes after non-curative endoscopic resection for esophageal squamous cell carcinoma followed by additional chemoradiotherapy.

IF 2.6 3区 医学 Diseases of the Esophagus Pub Date : 2024-04-27 DOI:10.1093/dote/doae004
Hourin Cho, Seiichiro Abe, Satoru Nonaka, Haruhisa Suzuki, Shigetaka Yoshinaga, Kae Okuma, Shun Yamamoto, Hiroyuki Daiko, Ken Kato, Shigeki Sekine, Narikazu Boku, Yutaka Saito
{"title":"Long-term outcomes after non-curative endoscopic resection for esophageal squamous cell carcinoma followed by additional chemoradiotherapy.","authors":"Hourin Cho, Seiichiro Abe, Satoru Nonaka, Haruhisa Suzuki, Shigetaka Yoshinaga, Kae Okuma, Shun Yamamoto, Hiroyuki Daiko, Ken Kato, Shigeki Sekine, Narikazu Boku, Yutaka Saito","doi":"10.1093/dote/doae004","DOIUrl":null,"url":null,"abstract":"<p><p>Endoscopic resection (ER) of esophageal squamous cell carcinoma (ESCC) is evaluated pathologically, and additional treatment is recommended for cases resulting in non-curative resection, defined as pMM with lymphovascular invasion (LVI), pSM, or positive vertical margin. This study aimed to assess long-term outcomes and risk factors for recurrence in patients with ESCC treated with non-curative ER followed by additional chemoradiotherapy (CRT). We retrospectively reviewed the clinical courses of patients who underwent non-curative ER followed by additional CRT for ESCCs between August 2007 and December 2017. Recurrence rates and risk factors for recurrence were analyzed. Among 97 patients with non-curative ER, 73 underwent additional CRT. With a median follow-up period of 71 months, recurrences were observed in 10 (14%) of 73 patients, with a median interval of 24.5 (1-59 months). The 3- and 5-year recurrence-free survival were 89 and 85%, respectively, and the 3- and 5-year overall survival rates were 96 and 91%, respectively. Multivariate analysis showed that lymphatic invasion was an independent risk factor for recurrence in patients with non-curative ESCC receiving additional CRT. Among the 10 patients with recurrence, 4, 3, 2, and 1 underwent surgery, chemotherapy, supportive care, and CRT, respectively. Notably, all four patients who underwent surgery survived, regardless of regional and/or distant lymph node metastasis. Lymphatic invasion is an independent risk factor for the recurrence of non-curative ESCCs. Careful follow-up is required for at least 5 years after ER with additional CRT.</p>","PeriodicalId":54277,"journal":{"name":"Diseases of the Esophagus","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diseases of the Esophagus","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/dote/doae004","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Endoscopic resection (ER) of esophageal squamous cell carcinoma (ESCC) is evaluated pathologically, and additional treatment is recommended for cases resulting in non-curative resection, defined as pMM with lymphovascular invasion (LVI), pSM, or positive vertical margin. This study aimed to assess long-term outcomes and risk factors for recurrence in patients with ESCC treated with non-curative ER followed by additional chemoradiotherapy (CRT). We retrospectively reviewed the clinical courses of patients who underwent non-curative ER followed by additional CRT for ESCCs between August 2007 and December 2017. Recurrence rates and risk factors for recurrence were analyzed. Among 97 patients with non-curative ER, 73 underwent additional CRT. With a median follow-up period of 71 months, recurrences were observed in 10 (14%) of 73 patients, with a median interval of 24.5 (1-59 months). The 3- and 5-year recurrence-free survival were 89 and 85%, respectively, and the 3- and 5-year overall survival rates were 96 and 91%, respectively. Multivariate analysis showed that lymphatic invasion was an independent risk factor for recurrence in patients with non-curative ESCC receiving additional CRT. Among the 10 patients with recurrence, 4, 3, 2, and 1 underwent surgery, chemotherapy, supportive care, and CRT, respectively. Notably, all four patients who underwent surgery survived, regardless of regional and/or distant lymph node metastasis. Lymphatic invasion is an independent risk factor for the recurrence of non-curative ESCCs. Careful follow-up is required for at least 5 years after ER with additional CRT.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
食管鳞状细胞癌非根治性内镜切除术后追加放化疗的长期疗效。
食管鳞状细胞癌(ESCC)的内镜下切除术(ER)需要进行病理评估,对于非根治性切除的病例建议进行额外治疗,非根治性切除的定义为伴有淋巴管侵犯(LVI)的pMM、pSM或垂直边缘阳性。本研究旨在评估ESCC患者接受非根治性ER治疗后追加化放疗(CRT)的长期疗效和复发风险因素。我们回顾性地回顾了2007年8月至2017年12月期间接受非根治性ER后附加CRT治疗的ESCC患者的临床病程。分析了复发率和复发的风险因素。在97名非根治性ER患者中,73人接受了额外的CRT治疗。中位随访期为71个月,73名患者中有10人(14%)复发,中位间隔为24.5个月(1-59个月)。3年和5年无复发生存率分别为89%和85%,3年和5年总生存率分别为96%和91%。多变量分析显示,淋巴侵犯是接受额外CRT治疗的非治愈性ESCC患者复发的独立风险因素。在10名复发患者中,分别有4人、3人、2人和1人接受了手术、化疗、支持治疗和CRT治疗。值得注意的是,无论有无区域和/或远处淋巴结转移,接受手术的四名患者全部存活。淋巴侵犯是非治愈性 ESCC 复发的独立风险因素。ER术后至少需要进行5年的仔细随访,并进行额外的CRT治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Diseases of the Esophagus
Diseases of the Esophagus Medicine-Gastroenterology
自引率
7.70%
发文量
568
期刊介绍: Diseases of the Esophagus covers all aspects of the esophagus - etiology, investigation and diagnosis, and both medical and surgical treatment.
期刊最新文献
Eosinophilic esophagitis prevalence, incidence, and presenting features: a 22-year population-based observational study from southwest Sweden. Exploring X: barriers to care for eosinophilic esophagitis. Effect of benralizumab on histopathology and inflammatory signatures in a clinical cohort of eosinophilic esophagitis. Identification of gaps in the delivery of high-quality care of patients with eosinophilic esophagitis. Increased expression of proton pump and allergic inflammation genes predicts PPI failure in pediatric eosinophilic esophagitis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1